CompletedPhase 3NCT00987389
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pennsylvania
- Principal Investigator
- David Jayne, MDCambridge University Hospitals NHS Foundation Trust
- Intervention
- Plasma Exchange(procedure)
- Enrollment
- 704 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2010 – 2017
Study locations (30)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Boston University School of Medicine, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Virginia, Charlottesville, Virginia, United States
- Canberra Hospital, Garran, Australian Capital Territory, Australia
- Concord Repatriation General Hospital, Concord, New South Wales, Australia
- John Hunter Hospital,, New Lambton Heights, New South Wales, Australia
- Prince of Wales Hospital, Randwick, New South Wales, Australia
- Royal North Shore Hospital, St Leonards, New South Wales, Australia
- Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Cambridge University Hospitals NHS Foundation Trust · University of Birmingham · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00987389 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →